167 related articles for article (PubMed ID: 22989279)
1. Pain is not associated with worse office-based buprenorphine treatment outcomes.
Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
[TBL] [Abstract][Full Text] [Related]
3. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
[TBL] [Abstract][Full Text] [Related]
4. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
Noe SR; Keller T
J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
6. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
[TBL] [Abstract][Full Text] [Related]
7. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE
Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429
[TBL] [Abstract][Full Text] [Related]
8. Trends In Buprenorphine Prescribing By Physician Specialty.
Wen H; Borders TF; Cummings JR
Health Aff (Millwood); 2019 Jan; 38(1):24-28. PubMed ID: 30615523
[TBL] [Abstract][Full Text] [Related]
9. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
10. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.
Mendelson J; Flower K; Pletcher MJ; Galloway GP
Exp Clin Psychopharmacol; 2008 Oct; 16(5):435-41. PubMed ID: 18837640
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
Shulman M; Wai JM; Nunes EV
CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
[TBL] [Abstract][Full Text] [Related]
12. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
[TBL] [Abstract][Full Text] [Related]
13. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Petrakis I; Rosenheck R
Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
[TBL] [Abstract][Full Text] [Related]
15. Comparison of behavioral treatment conditions in buprenorphine maintenance.
Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
[TBL] [Abstract][Full Text] [Related]
16. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study.
Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
Am J Addict; 2013; 22(3):212-7. PubMed ID: 23617861
[TBL] [Abstract][Full Text] [Related]
17. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Soyka M; Hillemacher T
Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
[No Abstract] [Full Text] [Related]
18. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
20. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
